Marker Therapeutics (NASDAQ:MRKR) PT Raised to $19.00 at LADENBURG THALM/SH SH

Marker Therapeutics (NASDAQ:MRKR) had its price objective boosted by LADENBURG THALM/SH SH from $11.00 to $19.00 in a research note issued on Monday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. LADENBURG THALM/SH SH’s price target would indicate a potential upside of 318.50% from the company’s previous close.

Marker Therapeutics Stock Performance

Marker Therapeutics stock opened at $4.54 on Monday. The stock’s 50-day moving average is $3.09 and its 200-day moving average is $3.97. Marker Therapeutics has a 12 month low of $2.40 and a 12 month high of $6.16.

Marker Therapeutics (NASDAQ:MRKR) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.25) EPS for the quarter. The firm had revenue of $1.17 million during the quarter. Marker Therapeutics had a negative return on equity of 78.91% and a negative net margin of 278.27%. Sell-side analysts expect that Marker Therapeutics will post -1.43 EPS for the current year.

Institutional Investors Weigh In On Marker Therapeutics

An institutional investor recently raised its position in Marker Therapeutics stock. Wedbush Securities Inc. lifted its stake in shares of Marker Therapeutics, Inc. (NASDAQ:MRKR) by 52.7% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 69,500 shares of the company’s stock after buying an additional 24,000 shares during the quarter. Wedbush Securities Inc. owned 0.78% of Marker Therapeutics worth $377,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 22.39% of the company’s stock.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.